Welcome to our dedicated page for ASLAN Pharmaceuticals American Depositary Shares news (Ticker: ASLN), a resource for investors and traders seeking the latest updates and insights on ASLAN Pharmaceuticals American Depositary Shares stock.
ASLAN Pharmaceuticals Limited (Nasdaq: ASLN) is a clinical-stage, immunology-focused biopharmaceutical company dedicated to developing innovative treatments that transform the lives of patients. Headquartered in Singapore with offices in Taiwan and China, ASLAN is tackling high-prevalence diseases in Asia and orphan indications in the United States and Europe.
ASLAN's strategic portfolio includes four product candidates targeting validated growth pathways, novel immune checkpoints, and cancer metabolic pathways. Their flagship projects are eblasakimab, a first-in-class antibody targeting the IL-13 receptor for moderate-to-severe atopic dermatitis (AD), and farudodstat, an oral inhibitor of the enzyme dihydroorotate dehydrogenase (DHODH) for alopecia areata (AA).
In recent developments, eblasakimab has shown promising results in a Phase 2b, dose-ranging study, achieving significant improvements in AD patients. Concurrently, farudodstat is progressing through a Phase 2a, proof-of-concept trial with interim results expected soon.
ASLAN actively collaborates with industry leaders such as Array BioPharma, Bristol-Myers Squibb, Almirall, and CSL to bolster their research and development efforts. The company's strategic alliances aim to leverage combined expertise for enhanced therapeutic outcomes.
On March 12, 2024, ASLAN announced a definitive agreement to sell 5,000,000 American Depositary Shares (ADSs) at $1.00 per ADS in a direct offering, with warrants issued in a concurrent private placement. The proceeds will fund ongoing R&D activities and general corporate purposes.
Despite financial challenges, including a reported deficit of $13.3 million in stockholders’ equity for 2023, ASLAN is committed to regaining compliance with Nasdaq listing requirements. This determination is underscored by their continuous efforts to advance their clinical pipeline and explore new research collaborations, such as their recent agreement with Zenyaku Kogyo Co., Ltd.
ASLAN's proactive approach, supported by a solid management team with deep global and regional expertise, aims to generate significant clinical advances and commercial opportunities. For more information, visit the ASLAN website or follow them on LinkedIn.
ASLAN Pharmaceuticals (Nasdaq: ASLN) announced that Dr. Carl Firth, CEO, will participate in one-on-one meetings and a fireside chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on March 30, 2023. The fireside chat is scheduled for 10:30am EST. An on-demand recording will be available on ASLAN's website. ASLAN is developing innovative treatments for autoimmune conditions, including eblasakimab and farudodstat.
ASLAN Pharmaceuticals (NASDAQ: ASLN) announced two abstracts on eblasakimab accepted for poster presentation at the 1st International Societies for Investigative Dermatology Meeting from May 10 to 13, 2023, in Tokyo, Japan. The posters will discuss eblasakimab’s clinical efficacy in treating difficult areas for atopic dermatitis, focusing on itch alleviation and sensory nerve modulation.
Notable posters include results from a Phase 1 study showing symptom improvement in moderate-to-severe atopic dermatitis and findings on targeting IL-13Rα1. The company is conducting a Phase 2b trial (TREK-AD) to evaluate eblasakimab, with topline results expected in July 2023.
ASLAN Pharmaceuticals (Nasdaq: ASLN) announced a change in its American Depositary Shares (ADS) ratio on March 10, 2023. The new ratio will be one ADS representing twenty-five ordinary shares, effectively a one-for-five reverse ADS split. This change is set to take place on March 13, 2023, and existing ADS holders will see their holdings automatically converted without needing action. There will be no fractional new ADSs issued; fractional entitlements will be sold, and proceeds distributed to ADS holders. While the ADS price is expected to increase proportionally, ASLAN cannot guarantee that it will be five times the current price.
ASLAN Pharmaceuticals (Nasdaq: ASLN) announced a virtual research and development day on March 16, 2023. Key Opinion Leader Brett King, MD PhD, from Yale University, will discuss alopecia areata (AA) and its treatment challenges. Following this, ASLAN's leadership will present updates on farudodstat, an oral DHODH inhibitor currently in a Phase 2 proof-of-concept trial for AA, aimed to begin in Q2 2023. Farudodstat has shown promise in inhibiting immune cell activity and protecting hair follicles. A live Q&A will follow, and registration is available online.
ASLAN Pharmaceuticals (Nasdaq: ASLN) is advancing farudodstat, a potent oral DHODH inhibitor, into a Phase 2 proof-of-concept trial for alopecia areata (AA), targeting an unmet medical need. The trial is set to enroll approximately 60 patients in the US starting in Q2 2023, with interim results expected by Q1 2024. Farudodstat has shown significant potency and a favorable safety profile, being 30 times more effective than existing DHODH inhibitors in preliminary tests. The company is hosting a virtual R&D Day on March 16, 2023, to discuss the treatment landscape and unmet needs in AA.
ASLAN Pharmaceuticals (Nasdaq: ASLN) has entered a purchase agreement to secure $20 million in financing, with potential additional funding of up to $80 million, aimed at advancing the clinical development of eblasakimab and farudodstat.
This financing extends ASLAN's cash runway through at least Q2 2024. Proceeds will support the ongoing TREK-AD study and the upcoming farudodstat trial.
Investors will acquire 112,359,550 ordinary shares at $0.178 each, with warrants exercisable following the announcement of trial data. The financing is expected to close around February 27, 2023.
ASLAN Pharmaceuticals has completed patient enrollment for the TREK-AD study, a Phase 2b clinical trial evaluating eblasakimab in adults with moderate-to-severe atopic dermatitis. The final patient was enrolled on February 24, 2023, with topline results expected in early July 2023. This randomized, double-blind, placebo-controlled study includes primary endpoints focusing on the percentage change in the Eczema Area Severity Index (EASI) score. The study aims to establish eblasakimab's potential as a first-choice biologic treatment in atopic dermatitis, complementing ongoing research in other patient populations.
ASLAN Pharmaceuticals (Nasdaq: ASLN) has partnered with Thermo Fisher Scientific to manufacture a high concentration formulation of eblasakimab for upcoming Phase 3 clinical trials. This formulation allows for up to 400mg to be delivered via a single injection, enhancing its administration. Manufacturing will start in January 2023 in Thermo Fisher's GMP-certified facilities. ASLAN's ongoing trials include the TREK-AD and TREK-DX studies, with topline data anticipated in 2023 and 2024, respectively, positioning eblasakimab as a potential groundbreaking treatment for atopic dermatitis.
ASLAN Pharmaceuticals (Nasdaq: ASLN) has announced its participation in several key conferences in January 2023. These events, including the BIO Partnering Conference and the 12th Annual LifeSci Partners Corporate Access Event, aim to facilitate one-on-one meetings with investors. The company is also focusing on its clinical programs, particularly the Phase 2b trial for eblasakimab, targeting moderate-to-severe atopic dermatitis, with results expected in 2Q 2023. Additionally, ASLAN plans to initiate a Phase 2 trial for farudodstat in skin autoimmune diseases in the first half of 2023.
ASLAN Pharmaceuticals (ASLN) has initiated the TREK-DX study to evaluate eblasakimab in patients with atopic dermatitis previously treated with dupilumab. This Phase 2 trial will enroll 75 patients in North America, with topline results expected in Q1 2024. The study is fully funded, ensuring no impact on ASLN's cash runway. Eblasakimab aims to provide a differentiated efficacy and safety profile by directly blocking the IL-13 receptor, potentially benefiting patients who lack effective treatment options.
FAQ
What is the current stock price of ASLAN Pharmaceuticals American Depositary Shares (ASLN)?
What is the market cap of ASLAN Pharmaceuticals American Depositary Shares (ASLN)?
What is ASLAN Pharmaceuticals' focus?
What are ASLAN Pharmaceuticals' main products?
Where is ASLAN Pharmaceuticals headquartered?
Who are ASLAN Pharmaceuticals’ partners?
What recent financial activities has ASLAN Pharmaceuticals undertaken?
What clinical advancements has ASLAN Pharmaceuticals made recently?
How is ASLAN Pharmaceuticals addressing its financial challenges?
What is the purpose of ASLAN Pharmaceuticals’ recent collaboration with Zenyaku Kogyo?
What is eblasakimab?
What are the potential benefits of farudodstat?
